Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma

Open Access

Peer-reviewed

Research Article

Yushi Zhang,

Affiliation Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
⨯
Yongqiang Li,

Affiliation Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
⨯
Jianhua Deng,

Affiliation Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
⨯
Zhigang Ji,

Affiliation Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
⨯
Hongyan Yu,

Affiliation Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
⨯
Hanzhong Li

* E-mail: lihanzhongpro@126.com

Affiliation Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
⨯

Reader Comments (0)

Renal cancer
Is the Subject Area "Renal cancer" applicable to this article?

Thanks for your feedback.
Renal cell carcinoma
Is the Subject Area "Renal cell carcinoma" applicable to this article?

Thanks for your feedback.
Surgical and invasive medical procedures
Is the Subject Area "Surgical and invasive medical procedures" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Surgical oncology
Is the Subject Area "Surgical oncology" applicable to this article?

Thanks for your feedback.
Metastasis
Is the Subject Area "Metastasis" applicable to this article?

Thanks for your feedback.